Approximately 30–40% of patients exhibit a switch between HER2-low and HER2–0 from primary tumor to relapse, and those acquiring HER2-low expression upon relapse may gain sensitivity to HER2-targeted therapies. Here, ERBB2 is linked to neoplasm.